Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineeringKathryn Michels, Shon Green, Christopher J. Nicolai et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 108
In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligandChristopher J. Nicolai, Byoung Y. Ryu, Maura H. Parker et al.|Blood|2024Cited by 102
Vivovec™ Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human Primates and Tumor-Bearing Humanized MiceMaura H. Parker, Byoung Y. Ryu, Justin Theophilus Ulrich-Lewis et al.|Blood|2023Cited by 7
1230 VivoVec lentiviral vector particles surface-engineered with T cell activating and co-stimulatory ligands enhance<i>in vivo</i>CAR T cell generation and antitumor activityChris Nicolai, Wai‐Hang Leung, Jim Qin et al.|Regular and Young Investigator Award Abstracts|2022Cited by 0